445 related articles for article (PubMed ID: 32416067)
1. Synthetic Lethal and Resistance Interactions with BET Bromodomain Inhibitors in Triple-Negative Breast Cancer.
Shu S; Wu HJ; Ge JY; Zeid R; Harris IS; Jovanović B; Murphy K; Wang B; Qiu X; Endress JE; Reyes J; Lim K; Font-Tello A; Syamala S; Xiao T; Reddy Chilamakuri CS; Papachristou EK; D'Santos C; Anand J; Hinohara K; Li W; McDonald TO; Luoma A; Modiste RJ; Nguyen QD; Michel B; Cejas P; Kadoch C; Jaffe JD; Wucherpfennig KW; Qi J; Liu XS; Long H; Brown M; Carroll JS; Brugge JS; Bradner J; Michor F; Polyak K
Mol Cell; 2020 Jun; 78(6):1096-1113.e8. PubMed ID: 32416067
[TBL] [Abstract][Full Text] [Related]
2. Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer.
Shu S; Lin CY; He HH; Witwicki RM; Tabassum DP; Roberts JM; Janiszewska M; Huh SJ; Liang Y; Ryan J; Doherty E; Mohammed H; Guo H; Stover DG; Ekram MB; Brown J; D'Santos C; Krop IE; Dillon D; McKeown M; Ott C; Qi J; Ni M; Rao PK; Duarte M; Wu SY; Chiang CM; Anders L; Young RA; Winer E; Letai A; Barry WT; Carroll JS; Long H; Brown M; Liu XS; Meyer CA; Bradner JE; Polyak K
Nature; 2016 Jan; 529(7586):413-417. PubMed ID: 26735014
[TBL] [Abstract][Full Text] [Related]
3. Anti-tumor activity of BET inhibitors in androgen-receptor-expressing triple-negative breast cancer.
Park IH; Yang HN; Jeon SY; Hwang JA; Kim MK; Kong SY; Shim SH; Lee KS
Sci Rep; 2019 Sep; 9(1):13305. PubMed ID: 31527644
[TBL] [Abstract][Full Text] [Related]
4. GSK2801, a BAZ2/BRD9 Bromodomain Inhibitor, Synergizes with BET Inhibitors to Induce Apoptosis in Triple-Negative Breast Cancer.
Bevill SM; Olivares-Quintero JF; Sciaky N; Golitz BT; Singh D; Beltran AS; Rashid NU; Stuhlmiller TJ; Hale A; Moorman NJ; Santos CM; Angus SP; Zawistowski JS; Johnson GL
Mol Cancer Res; 2019 Jul; 17(7):1503-1518. PubMed ID: 31000582
[TBL] [Abstract][Full Text] [Related]
5. Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer.
Noblejas-López MDM; Nieto-Jimenez C; Burgos M; Gómez-Juárez M; Montero JC; Esparís-Ogando A; Pandiella A; Galán-Moya EM; Ocaña A
J Exp Clin Cancer Res; 2019 Aug; 38(1):383. PubMed ID: 31470872
[TBL] [Abstract][Full Text] [Related]
6. Transcriptional plasticity promotes primary and acquired resistance to BET inhibition.
Rathert P; Roth M; Neumann T; Muerdter F; Roe JS; Muhar M; Deswal S; Cerny-Reiterer S; Peter B; Jude J; Hoffmann T; Boryń ŁM; Axelsson E; Schweifer N; Tontsch-Grunt U; Dow LE; Gianni D; Pearson M; Valent P; Stark A; Kraut N; Vakoc CR; Zuber J
Nature; 2015 Sep; 525(7570):543-547. PubMed ID: 26367798
[TBL] [Abstract][Full Text] [Related]
7. BET proteins regulate homologous recombination-mediated DNA repair: BRCAness and implications for cancer therapy.
Mio C; Gerratana L; Bolis M; Caponnetto F; Zanello A; Barbina M; Di Loreto C; Garattini E; Damante G; Puglisi F
Int J Cancer; 2019 Feb; 144(4):755-766. PubMed ID: 30259975
[TBL] [Abstract][Full Text] [Related]
8. BET Proteins Exhibit Transcriptional and Functional Opposition in the Epithelial-to-Mesenchymal Transition.
Andrieu GP; Denis GV
Mol Cancer Res; 2018 Apr; 16(4):580-586. PubMed ID: 29437854
[TBL] [Abstract][Full Text] [Related]
9. DUB3 Promotes BET Inhibitor Resistance and Cancer Progression by Deubiquitinating BRD4.
Jin X; Yan Y; Wang D; Ding D; Ma T; Ye Z; Jimenez R; Wang L; Wu H; Huang H
Mol Cell; 2018 Aug; 71(4):592-605.e4. PubMed ID: 30057199
[TBL] [Abstract][Full Text] [Related]
10. Acquired resistance to combined BET and CDK4/6 inhibition in triple-negative breast cancer.
Ge JY; Shu S; Kwon M; Jovanović B; Murphy K; Gulvady A; Fassl A; Trinh A; Kuang Y; Heavey GA; Luoma A; Paweletz C; Thorner AR; Wucherpfennig KW; Qi J; Brown M; Sicinski P; McDonald TO; Pellman D; Michor F; Polyak K
Nat Commun; 2020 May; 11(1):2350. PubMed ID: 32393766
[TBL] [Abstract][Full Text] [Related]
11. BRD4 modulates vulnerability of triple-negative breast cancer to targeting of integrin-dependent signaling pathways.
Zhang Y; Xu B; Shi J; Li J; Lu X; Xu L; Yang H; Hamad N; Wang C; Napier D; He S; Liu C; Liu Z; Qian H; Chen L; Wei X; Zheng X; Huang JA; Thibault O; Craven R; Wei D; Pan Y; Zhou BP; Wu Y; Yang XH
Cell Oncol (Dordr); 2020 Dec; 43(6):1049-1066. PubMed ID: 33006750
[TBL] [Abstract][Full Text] [Related]
12. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma.
Loganathan SN; Tang N; Fleming JT; Ma Y; Guo Y; Borinstein SC; Chiang C; Wang J
Oncotarget; 2016 Jul; 7(28):43504-43517. PubMed ID: 27259270
[TBL] [Abstract][Full Text] [Related]
13. LIN9 confers paclitaxel resistance in triple negative breast cancer cells by upregulating CCSAP.
Lai H; Wang R; Li S; Shi Q; Cai Z; Li Y; Liu Y
Sci China Life Sci; 2020 Mar; 63(3):419-428. PubMed ID: 31420851
[TBL] [Abstract][Full Text] [Related]
14. FGFR-inhibitor-mediated dismissal of SWI/SNF complexes from YAP-dependent enhancers induces adaptive therapeutic resistance.
Li Y; Qiu X; Wang X; Liu H; Geck RC; Tewari AK; Xiao T; Font-Tello A; Lim K; Jones KL; Morrow M; Vadhi R; Kao PL; Jaber A; Yerrum S; Xie Y; Chow KH; Cejas P; Nguyen QD; Long HW; Liu XS; Toker A; Brown M
Nat Cell Biol; 2021 Nov; 23(11):1187-1198. PubMed ID: 34737445
[TBL] [Abstract][Full Text] [Related]
15. Identification of a stemness-related gene panel associated with BET inhibition in triple negative breast cancer.
Serrano-Oviedo L; Nuncia-Cantarero M; Morcillo-Garcia S; Nieto-Jimenez C; Burgos M; Corrales-Sanchez V; Perez-Peña J; Győrffy B; Ocaña A; Galán-Moya EM
Cell Oncol (Dordr); 2020 Jun; 43(3):431-444. PubMed ID: 32166583
[TBL] [Abstract][Full Text] [Related]
16. BRD4 inhibition suppresses PD-L1 expression in triple-negative breast cancer.
Jing X; Shao S; Zhang Y; Luo A; Zhao L; Zhang L; Gu S; Zhao X
Exp Cell Res; 2020 Jul; 392(2):112034. PubMed ID: 32339606
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of the mitotic kinase PLK1 overcomes therapeutic resistance to BET inhibitors in triple negative breast cancer.
Nieto-Jimenez C; Galan-Moya EM; Corrales-Sanchez V; Noblejas-Lopez MDM; Burgos M; Domingo B; Montero JC; Gomez-Juarez M; Picazo-Martinez MG; Esparis-Ogando A; Pandiella A; Ocaña A
Cancer Lett; 2020 Oct; 491():50-59. PubMed ID: 32735909
[TBL] [Abstract][Full Text] [Related]
18. Co-targeting BET bromodomain BRD4 and RAC1 suppresses growth, stemness and tumorigenesis by disrupting the c-MYC-G9a-FTH1axis and downregulating HDAC1 in molecular subtypes of breast cancer.
Ali A; Shafarin J; Unnikannan H; Al-Jabi N; Jabal RA; Bajbouj K; Muhammad JS; Hamad M
Int J Biol Sci; 2021; 17(15):4474-4492. PubMed ID: 34803511
[TBL] [Abstract][Full Text] [Related]
19. In Silico Analysis Guides Selection of BET Inhibitors for Triple-Negative Breast Cancer Treatment.
Pérez-Peña J; Serrano-Heras G; Montero JC; Corrales-Sánchez V; Pandiella A; Ocaña A
Mol Cancer Ther; 2016 Aug; 15(8):1823-33. PubMed ID: 27256375
[TBL] [Abstract][Full Text] [Related]
20. Sensitivity of Small Cell Lung Cancer to BET Inhibition Is Mediated by Regulation of ASCL1 Gene Expression.
Lenhart R; Kirov S; Desilva H; Cao J; Lei M; Johnston K; Peterson R; Schweizer L; Purandare A; Ross-Macdonald P; Fairchild C; Wong T; Wee S
Mol Cancer Ther; 2015 Oct; 14(10):2167-74. PubMed ID: 26253517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
